Cell Therapy Trials in Congenital Heart Disease

Circulation Research

Volumn 120, Issue 8, 2017, Pages 1353-1366

  Oh, Hidemasa ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

dilated cardiomyopathy; general practice; hypoplastic left heart syndrome; prevalence; stem cell

Indexed keywords

CARDIOVASCULAR MORTALITY; CELL THERAPY; CLINICAL TRIAL (TOPIC); CONGENITAL HEART DISEASE; DEVICE THERAPY; HEART FAILURE; HEART FUNCTION; HEART SINGLE VENTRICLE; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE FUNCTION; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PRECLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; ABNORMALITIES; ADVERSE EFFECTS; CONVALESCENCE; FORECASTING; HEART DEFECTS, CONGENITAL; HEART VENTRICLE; MASS COMMUNICATION; MORTALITY; PATHOPHYSIOLOGY; PROCEDURES; REGENERATION; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

CLINICAL TRIALS AS TOPIC; DIFFUSION OF INNOVATION; FORECASTING; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMANS; RECOVERY OF FUNCTION; REGENERATION; RISK FACTORS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 85017446577     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.309697     Document Type: Review

References (162)

1. Barron DJ, Kilby MD, Davies B, Wright JG, Jones TJ, Brawn WJ, Hypoplastic left heart syndrome. Lancet 2009 374 551 564. doi: 10.1016/S0140-6736(09)60563-8.
2. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M, Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 2014 130 749 756. doi: 10.1161/CIRCULATIONAHA.113.008396.
3. Nguyen PK, Rhee JW, Wu JC, Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol 2016 1 831 841. doi: 10.1001/jamacardio.2016.2225.
4. Anversa P, Kajstura J, Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res 1998 83 1 14
5. Bergmann O, Zdunek S, Felker A, Dynamics of Cell Generation and Turnover in the Human Heart. Cell 2015 161 1566 1575. doi: 10.1016/j.cell.2015.05.026.
6. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA, Transient regenerative potential of the neonatal mouse heart. Science 2011 331 1078 1080. doi: 10.1126/science.1200708.
7. Mahmoud AI, Kocabas F, Muralidhar SA, Kimura W, Koura AS, Thet S, Porrello ER, Sadek HA, Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature 2013 497 249 253. doi: 10.1038/nature12054.
8. Ptaszek LM, Mansour M, Ruskin JN, Chien KR, Towards regenerative therapy for cardiac disease. Lancet 2012 379 933 942. doi: 10.1016/S0140-6736(12)60075-0.
9. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E, Frati L, Cossu G, Giacomello A, Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004 95 911 921. doi: 10.1161/01.RES.0000147315.71699.51.
10. Bearzi C, Rota M, Hosoda T, Human cardiac stem cells. Proc Natl Acad Sci USA 2007 104 14068 14073. doi: 10.1073/pnas.0706760104.
11. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, Matsushita N, Blusztajn A, Terrovitis J, Kusuoka H, Marbán L, Marbán E, Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 2012 59 942 953. doi: 10.1016/j.jacc.2011.11.029.
12. Mishra R, Vijayan K, Colletti EJ, Harrington DA, Matthiesen TS, Simpson D, Goh SK, Walker BL, Almeida-Porada G, Wang D, Backer CL, Dudley SC Jr, Wold LE, Kaushal S, Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation 2011 123 364 373. doi: 10.1161/CIRCULATIONAHA.110.971622.
13. Simpson DL, Mishra R, Sharma S, Goh SK, Deshmukh S, Kaushal S, A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation 2012 126 S46 S53. doi: 10.1161/CIRCULATIONAHA.111.084699.
14. Sharma S, Mishra R, Bigham GE, A Deep Proteome Analysis Identifies the Complete Secretome as the Functional Unit of Human Cardiac Progenitor Cells. Circ Res 2017 120 816 834. doi: 10.1161/CIRCRESAHA.116.309782.
15. Barile L, Moccetti T, Marban E, Vassalli G, Roles of exosomes in cardioprotection [published online ahead of print July 21, 2016]. Eur Heart J. doi: https://doi.org/10.1093/eurheartj/ehw304. https://academic.oup.com/eurheartj/article-abstract/doi/10.1093/eurheartj/ehw304/3056933/Roles-of-exosomes-in-cardioprotection?redirectedFrom=fulltext
16. Smart N, Bollini S, Dubé KN, Vieira JM, Zhou B, Davidson S, Yellon D, Riegler J, Price AN, Lythgoe MF, Pu WT, Riley PR, De novo cardiomyocytes from within the activated adult heart after injury. Nature 2011 474 640 644. doi: 10.1038/nature10188.
17. Wei K, Serpooshan V, Hurtado C, Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 2015 525 479 485. doi: 10.1038/nature15372.
18. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJ, The changing epidemiology of congenital heart disease. Nat Rev Cardiol 2011 8 50 60. doi: 10.1038/nrcardio.2010.166.
19. Best KE, Rankin J, Long-term survival of individuals born with congenital heart disease: a systematic review and meta-analysis. J Am Heart Assoc 2016 5 e002846. doi: 10.1161/AHA.115.002846.
20. Gilboa SM, Salemi JL, Nembhard WN, Fixler DE, Correa A, Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. Circulation 2010 122 2254 2263. doi: 10.1161/CIRCULATIONAHA.110.947002.
21. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L, Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007 115 163 172. doi: 10.1161/CIRCULATIONAHA.106.627224.
22. Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E, Late causes of death after pediatric cardiac surgery: A 60-Year Population-Based Study. J Am Coll Cardiol 2016 68 487 498. doi: 10.1016/j.jacc.2016.05.038.
23. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, Vliegen HW, Grobbee DE, Mulder BJ, Mortality in adult congenital heart disease. Eur Heart J 2010 31 1220 1229. doi: 10.1093/eurheartj/ehq032.
24. Zomer AC, Vaartjes I, van der Velde ET, de Jong HM, Konings TC, Wagenaar LJ, Heesen WF, Eerens F, Baur LH, Grobbee DE, Mulder BJ, Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. Int J Cardiol 2013 168 2487 2493. doi: 10.1016/j.ijcard.2013.03.003.
25. Ohye RG, Sleeper LA, Mahony L, Pediatric Heart Network Investigators Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med 2010 362 1980 1992. doi: 10.1056/NEJMoa0912461.
26. Newburger JW, Sleeper LA, Frommelt PC, Pediatric Heart Network Investigators Transplantation-free survival and interventions at 3 years in the single ventricle reconstruction trial. Circulation 2014 129 2013 2020. doi: 10.1161/CIRCULATIONAHA.113.006191.
27. Tweddell JS, Sleeper LA, Ohye RG, Pediatric Heart Network Investigators Intermediate-term mortality and cardiac transplantation in infants with single-ventricle lesions: risk factors and their interaction with shunt type. J Thorac Cardiovasc Surg 2012 144 152 159. doi: 10.1016/j.jtcvs.2012.01.016.
28. Gibbs JL, Wren C, Watterson KG, Hunter S, Hamilton JR, Stenting of the arterial duct combined with banding of the pulmonary arteries and atrial septectomy or septostomy: a new approach to palliation for the hypoplastic left heart syndrome. Br Heart J 1993 69 551 555
29. Baba K, Kotani Y, Chetan D, Chaturvedi RR, Lee KJ, Benson LN, Grosse-Wortmann L, Van Arsdell GS, Caldarone CA, Honjo O, Hybrid versus Norwood strategies for single-ventricle palliation. Circulation 2012 126 S123 S131. doi: 10.1161/CIRCULATIONAHA.111.084616.
30. Chetan D, Kotani Y, Jacques F, Poynter JA, Benson LN, Lee KJ, Chaturvedi RR, Friedberg MK, Van Arsdell GS, Caldarone CA, Honjo O, Surgical palliation strategy does not affect interstage ventricular dysfunction or atrioventricular valve regurgitation in children with hypoplastic left heart syndrome and variants. Circulation 2013 128 S205 S212. doi: 10.1161/CIRCULATIONAHA.112.000380.
31. d'Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, Bullock A, Justo RN, Grigg LE, Sholler GF, Hope S, Radford DJ, Gentles TL, Celermajer DS, Winlaw DS, Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation 2014 130 S32 S38. doi: 10.1161/CIRCULATIONAHA.113.007764.
32. Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, Dahl SH, Cannon BC, O'Leary PW, Driscoll DJ, Cetta F, 40-Year follow-up after the Fontan operation: long-term outcomes of 1,052 patients. J Am Coll Cardiol 2015 66 1700 1710. doi: 10.1016/j.jacc.2015.07.065.
33. Stout KK, Broberg CS, Book WM, American Heart Association Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, and Council on Cardiovascular Radiology and Imaging Chronic Heart Failure in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation 2016 133 770 801. doi: 10.1161/CIR.0000000000000352.
34. Bridges ND, Lock JE, Castaneda AR, Baffle fenestration with subsequent transcatheter closure. Modification of the Fontan operation for patients at increased risk. Circulation 1990 82 1681 1689
35. Piran S, Veldtman G, Siu S, Webb GD, Liu PP, Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation 2002 105 1189 1194
36. Anderson PA, Sleeper LA, Mahony L, Pediatric Heart Network Investigators Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol 2008 52 85 98. doi: 10.1016/j.jacc.2008.01.074.
37. Gelow JM, Song HK, Weiss JB, Mudd JO, Broberg CS, Organ allocation in adults with congenital heart disease listed for heart transplant: impact of ventricular assist devices. J Heart Lung Transplant 2013 32 1059 1064. doi: 10.1016/j.healun.2013.06.024.
38. Ross HJ, Law Y, Book WM, American Heart Association Adults With Congenital Heart Disease Committee of the Council on Clinical Cardiology and Council on Cardiovascular Disease in the Young, the Council on Cardiovascular Radiology and Intervention, and the Council on Functional Genomics and Translational Biology Transplantation and Mechanical Circulatory Support in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation 2016 133 802 820. doi: 10.1161/CIR.0000000000000353.
39. Schranz D, Bauer A, Reich B, Steinbrenner B, Recla S, Schmidt D, Apitz C, Thul J, Valeske K, Bauer J, Müller M, Jux C, Michel-Behnke I, Akintürk H, Fifteen-year single center experience with the "Giessen Hybrid" approach for hypoplastic left heart and variants: current strategies and outcomes. Pediatr Cardiol 2015 36 365 373. doi: 10.1007/s00246-014-1015-2.
40. Murphy MO, Bellsham-Revell H, Morgan GJ, Krasemann T, Rosenthal E, Qureshi SA, Salih C, Austin CB, Anderson DR, Hybrid procedure for neonates with hypoplastic left heart syndrome at high-risk for Norwood: midterm outcomes. Ann Thorac Surg 2015 100 2286 2290. discussion 2291. doi: 10.1016/j.athoracsur.2015.06.098.
41. Jacobs JP, Quintessenza JA, Chai PJ, Lindberg HL, Asante-Korang A, McCormack J, Dadlani G, Boucek RJ, Rescue cardiac transplantation for failing staged palliation in patients with hypoplastic left heart syndrome. Cardiol Young 2006 16 556 562. doi: 10.1017/S1047951106001223.
42. Michielon G, Parisi F, Squitieri C, Carotti A, Gagliardi G, Pasquini L, Di Donato RM, Orthotopic heart transplantation for congenital heart disease: an alternative for high-risk Fontan candidates? Circulation 2003 108 Suppl 1 II140 II149
43. Lamour JM, Kanter KR, Naftel DC, Chrisant MR, Morrow WR, Clemson BS, Kirklin JK, Cardiac Transplant Registry Database; Pediatric Heart Transplant Study The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol 2009 54 160 165. doi: 10.1016/j.jacc.2009.04.020.
44. Davies RR, Sorabella RA, Yang J, Mosca RS, Chen JM, Quaegebeur JM, Outcomes after transplantation for "failed" Fontan: a single-institution experience. J Thorac Cardiovasc Surg 2012 143 1183 1192.e4. doi: 10.1016/j.jtcvs.2011.12.039.
45. Alsoufi B, Mahle WT, Manlhiot C, Deshpande S, Kogon B, McCrindle BW, Kanter K, Outcomes of heart transplantation in children with hypoplastic left heart syndrome previously palliated with the Norwood procedure. J Thorac Cardiovasc Surg 2016 151 167 174. 175 e1-2
46. Shi WY, Yong MS, McGiffin DC, Jain P, Ruygrok PN, Marasco SF, Finucane K, Keogh A, d'Udekem Y, Weintraub RG, Konstantinov IE, Heart transplantation in Fontan patients across Australia and New Zealand. Heart 2016 102 1120 1126. doi: 10.1136/heartjnl-2015-308848.
47. Shaddy RE, Boucek MM, Hsu DT, Pediatric Carvedilol Study G Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007 298 1171 1179
48. Ishibashi N, Park IS, Waragai T, Yoshikawa T, Murakami Y, Mori K, Mimori S, Ando M, Takahashi Y, Doi S, Mizutani S, Nakanishi T, Effect of carvedilol on heart failure in patients with a functionally univentricular heart. Circ J 2011 75 1394 1399
49. Hsu DT, Zak V, Mahony L, Pediatric Heart Network Investigators Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation 2010 122 333 340. doi: 10.1161/CIRCULATIONAHA.109.927988.
50. Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, Marcotte F, Mercier LA, Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 2005 112 2411 2416. doi: 10.1161/CIRCULATIONAHA.105.543470.
51. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM, Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008 29 1681 1687. doi: 10.1093/eurheartj/ehn215.
52. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J, Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011 123 1185 1193. doi: 10.1161/CIRCULATIONAHA.110.981746.
53. Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sørensen KE, Søndergaard L, Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation 2014 130 2021 2030. doi: 10.1161/CIRCULATIONAHA.113.008441.
54. Janousek J, Gebauer RA, Abdul-Khaliq H, Working Group for Cardiac Dysrhythmias and Electrophysiology of the Association for European Paediatric Cardiology Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009 95 1165 1171. doi: 10.1136/hrt.2008.160465.
55. Dubin AM, Feinstein JA, Reddy VM, Hanley FL, Van Hare GF, Rosenthal DN, Electrical resynchronization: a novel therapy for the failing right ventricle. Circulation 2003 107 2287 2289. doi: 10.1161/01.CIR.0000070930.33499.9F.
56. Dubin AM, Janousek J, Rhee E, Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2005 46 2277 2283. doi: 10.1016/j.jacc.2005.05.096.
57. Cecchin F, Frangini PA, Brown DW, Fynn-Thompson F, Alexander ME, Triedman JK, Gauvreau K, Walsh EP, Berul CI, Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. J Cardiovasc Electrophysiol 2009 20 58 65. doi: 10.1111/j.1540-8167.2008.01274.x.
58. Motonaga KS, Miyake CY, Punn R, Rosenthal DN, Dubin AM, Insights into dyssynchrony in hypoplastic left heart syndrome. Heart Rhythm 2012 9 2010 2015. doi: 10.1016/j.hrthm.2012.08.031.
59. Joyce DL, Crow SS, John R, St Louis JD, Braunlin EA, Pyles LA, Kofflin P, Joyce LD, Mechanical circulatory support in patients with heart failure secondary to transposition of the great arteries. J Heart Lung Transplant 2010 29 1302 1305. doi: 10.1016/j.healun.2010.05.030.
60. Neely RC, Davis RP, Stephens EH, Takayama H, Khalpey Z, Ginns J, Lee SH, Chen J, Ventricular assist device for failing systemic ventricle in an adult with prior mustard procedure. Ann Thorac Surg 2013 96 691 693. doi: 10.1016/j.athoracsur.2012.12.049.
61. Weinstein S, Bello R, Pizarro C, Fynn-Thompson F, Kirklin J, Guleserian K, Woods R, Tjossem C, Kroslowitz R, Friedmann P, Jaquiss R, The use of the Berlin Heart EXCOR in patients with functional single ventricle. J Thorac Cardiovasc Surg 2014 147 697 704. discussion 704. doi: 10.1016/j.jtcvs.2013.10.030.
62. Wehman B, Kaushal S, The emergence of stem cell therapy for patients with congenital heart disease. Circ Res 2015 116 566 569. doi: 10.1161/CIRCRESAHA.115.305821.
63. Borenstein N, Jian Z, Fromont G, Bruneval P, Hekmati M, Behr L, Laborde F, Montarras D, Le Bret E, Noncultured cell transplantation in an ovine model of right ventricular preparation. J Thorac Cardiovasc Surg 2005 129 1119 1127. doi: 10.1016/j.jtcvs.2004.09.008.
64. Hoashi T, Matsumiya G, Miyagawa S, Ichikawa H, Ueno T, Ono M, Saito A, Shimizu T, Okano T, Kawaguchi N, Matsuura N, Sawa Y, Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart. J Thorac Cardiovasc Surg 2009 138 460 467. doi: 10.1016/j.jtcvs.2009.02.018.
65. Cantero Peral S, Burkhart HM, Oommen S, Yamada S, Nyberg SL, Li X, O'Leary PW, Terzic A, Cannon BC, Nelson TJ, Wanek Program Porcine Pipeline Group Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system. Stem Cells Transl Med 2015 4 195 206. doi: 10.5966/sctm.2014-0195.
66. Davies B, Elwood NJ, Li S, Cullinane F, Edwards GA, Newgreen DF, Brizard CP, Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training. Ann Thorac Surg 2010 89 585 93, 593.e1. doi: 10.1016/j.athoracsur.2009.10.035.
67. Kajstura J, Gurusamy N, Ogórek B, Myocyte turnover in the aging human heart. Circ Res 2010 107 1374 1386. doi: 10.1161/CIRCRESAHA.110.231498.
68. Tallini YN, Greene KS, Craven M, Spealman A, Breitbach M, Smith J, Fisher PJ, Steffey M, Hesse M, Doran RM, Woods A, Singh B, Yen A, Fleischmann BK, Kotlikoff MI, c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci USA 2009 106 1808 1813. doi: 10.1073/pnas.0808920106.
69. Zaruba MM, Soonpaa M, Reuter S, Field LJ, Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 2010 121 1992 2000. doi: 10.1161/CIRCULATIONAHA.109.909093.
70. van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC, Middleton RC, Marbán E, Molkentin JD, c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014 509 337 341. doi: 10.1038/nature13309.
71. Sultana N, Zhang L, Yan J, Chen J, Cai W, Razzaque S, Jeong D, Sheng W, Bu L, Xu M, Huang GY, Hajjar RJ, Zhou B, Moon A, Cai CL, Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun 2015 6 8701. doi: 10.1038/ncomms9701.
72. White AJ, Smith RR, Matsushita S, Chakravarty T, Czer LS, Burton K, Schwarz ER, Davis DR, Wang Q, Reinsmoen NL, Forrester JS, Marbán E, Makkar R, Intrinsic cardiac origin of human cardiosphere-derived cells. Eur Heart J 2013 34 68 75. doi: 10.1093/eurheartj/ehr172.
73. Tateishi K, Ashihara E, Honsho S, Takehara N, Nomura T, Takahashi T, Ueyama T, Yamagishi M, Yaku H, Matsubara H, Oh H, Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun 2007 352 635 641. doi: 10.1016/j.bbrc.2006.11.096.
74. Davis DR, Zhang Y, Smith RR, Cheng K, Terrovitis J, Malliaras K, Li TS, White A, Makkar R, Marbán E, Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One 2009 4 e7195. doi: 10.1371/journal.pone.0007195.
75. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, Marbán E, Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010 106 971 980. doi: 10.1161/CIRCRESAHA.109.210682.
76. Cheng K, Ibrahim A, Hensley MT, Shen D, Sun B, Middleton R, Liu W, Smith RR, Marbán E, Relative roles of CD90 and c-kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. J Am Heart Assoc 2014 3 e001260. doi: 10.1161/JAHA.114.001260.
77. Takehara N, Tsutsumi Y, Tateishi K, Ogata T, Tanaka H, Ueyama T, Takahashi T, Takamatsu T, Fukushima M, Komeda M, Yamagishi M, Yaku H, Tabata Y, Matsubara H, Oh H, Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol 2008 52 1858 1865. doi: 10.1016/j.jacc.2008.06.052.
78. Johnston PV, Sasano T, Mills K, Evers R, Lee ST, Smith RR, Lardo AC, Lai S, Steenbergen C, Gerstenblith G, Lange R, Marbán E, Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009 120 1075 1083. doi: 10.1161/CIRCULATIONAHA.108.816058.
79. Bolli R, Tang XL, Sanganalmath SK, Rimoldi O, Mosna F, Abdel-Latif A, Jneid H, Rota M, Leri A, Kajstura J, Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013 128 122 131. doi: 10.1161/CIRCULATIONAHA.112.001075.
80. Bolli R, Chugh AR, D'Amario D, Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011 378 1847 1857. doi: 10.1016/S0140-6736(11)61590-0.
81. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E, Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012 379 895 904. doi: 10.1016/S0140-6736(12)60195-0.
82. Sanganalmath SK, Bolli R, Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013 113 810 834. doi: 10.1161/CIRCRESAHA.113.300219.
83. Chakravarty T, Makkar R, Henry T, Kittleson M, Friedman J, Berman D, Lima J, Malliaras K, Siegel R, Slipczuk L, Rudy J, Marban E, Pogoda J, Marban L, Ascheim D, TCT-820 multivessel intracoronary infusion of allogeneic cardiosphere derived cells in dilated cardiomyopathy: long term outcomes of the Dilated Cardiomyopathy Intervention with Allogeneic Myocardially-Regenerative Cells (DYNAMIC Trial). J Am Coll Cardiol 2016 68 B332. doi: 10.1016/j.jacc.2016.09.848.
84. Williams AR, Hare JM, Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011 109 923 940. doi: 10.1161/CIRCRESAHA.111.243147.
85. Wehman B, Sharma S, Pietris N, Mishra R, Siddiqui OT, Bigham G, Li T, Aiello E, Murthi S, Pittenger M, Griffith B, Kaushal S, Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload. Am J Physiol Heart Circ Physiol 2016 310 H1816 H1826. doi: 10.1152/ajpheart.00955.2015.
86. Suzuki K, Murtuza B, Suzuki N, Smolenski RT, Yacoub MH, Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation 2001 104 I213 I217
87. Pouly J, Hagège AA, Vilquin JT, Bissery A, Rouche A, Bruneval P, Duboc D, Desnos M, Fiszman M, Fromes Y, Menasché P, Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy? Circulation 2004 110 1626 1631. doi: 10.1161/01.CIR.0000142861.55862.15.
88. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, Fujii T, Uematsu M, Ohgushi H, Yamagishi M, Tokudome T, Mori H, Miyatake K, Kitamura S, Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005 112 1128 1135. doi: 10.1161/CIRCULATIONAHA.104.500447.
89. Li L, Zhang Y, Li Y, Yu B, Xu Y, Zhao S, Guan Z, Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int 2008 21 1181 1189. doi: 10.1111/j.1432-2277.2008.00742.x.
90. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P, Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010 121 276 292. doi: 10.1161/CIRCULATIONAHA.109.895771.
91. Aminzadeh MA, Tseliou E, Sun B, Cheng K, Malliaras K, Makkar RR, Marbán E, Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy. Eur Heart J 2015 36 751 762. doi: 10.1093/eurheartj/ehu196.
92. Gong X, Wang P, Wu Q, Wang S, Yu L, Wang G, Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W) transgenic mouse of dilated cardiomyopathy. Eur J Cell Biol 2016 95 57 67. doi: 10.1016/j.ejcb.2015.11.003.
93. Tarui S, Sano S, Oh H, Stem cell therapies in patients with single ventricle physiology. Methodist Debakey Cardiovasc J 2014 10 77 81
94. Rupp S, Bauer J, Tonn T, Schächinger V, Dimmeler S, Zeiher AM, Schranz D, Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr Transplant 2009 13 620 623. doi: 10.1111/j.1399-3046.2008.01024.x.
95. Lacis A, Erglis A, Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy. Cardiol Young 2011 21 110 112. doi: 10.1017/S1047951110001435.
96. Olguntürk R, Kula S, Sucak GT, Ozdoǧan ME, Erer D, Saygili A, Peripheric stem cell transplantation in children with dilated cardiomyopathy: preliminary report of first two cases. Pediatr Transplant 2010 14 257 260. doi: 10.1111/j.1397-3142.2009.01215.x.
97. Rupp S, Jux C, Bönig H, Bauer J, Tonn T, Seifried E, Dimmeler S, Zeiher AM, Schranz D, Intracoronary bone marrow cell application for terminal heart failure in children. Cardiol Young 2012 22 558 563. doi: 10.1017/S1047951112000066.
98. Rupp S, Zeiher AM, Dimmeler S, Tonn T, Bauer J, Jux C, Akintuerk H, Schranz D, A regenerative strategy for heart failure in hypoplastic left heart syndrome: intracoronary administration of autologous bone marrow-derived progenitor cells. J Heart Lung Transplant 2010 29 574 577. doi: 10.1016/j.healun.2009.10.006.
99. Limsuwan A, Pienvichit P, Limpijankit T, Khowsathit P, Hongeng S, Pornkul R, Siripornpitak S, Boonbaichaiyapruk S, Transcoronary bone marrow-derived progenitor cells in a child with myocardial infarction: first pediatric experience. Clin Cardiol 2010 33 E7 12. doi: 10.1002/clc.20463.
100. Burkhart HM, Qureshi MY, Peral SC, O'Leary PW, Olson TM, Cetta F, Nelson TJ, Wanek Program Clinical Pipeline Group Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells. J Thorac Cardiovasc Surg 2015 149 e35 e37. doi: 10.1016/j.jtcvs.2014.10.093.
101. Bergmane I, Lacis A, Lubaua I, Jakobsons E, Erglis A, Follow-up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy. Pediatr Transplant 2013 17 266 270. doi: 10.1111/petr.12055.
102. Agarwal U, Smith AW, French KM, Age-Dependent Effect of Pediatric Cardiac Progenitor Cells After Juvenile Heart Failure. Stem Cells Transl Med 2016 5 883 892. doi: 10.5966/sctm.2015-0241.
103. Wehman B, Sharma S, Mishra R, Guo Y, Colletti EJ, Kon ZN, Datla SR, Siddiqui OT, Balachandran K, Kaushal S, Pediatric end-stage failing hearts demonstrate increased cardiac stem cells. Ann Thorac Surg 2015 100 615 622. doi: 10.1016/j.athoracsur.2015.04.088.
104. Ishigami S, Ohtsuki S, Tarui S, Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 2015 116 653 664. doi: 10.1161/CIRCRESAHA.116.304671.
105. Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H, Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg 2015 150 1198 1207, 1208.e1. doi: 10.1016/j.jtcvs.2015.06.076.
106. Ishigami S, Ohtsuki S, Eitoku T, Intracoronary cardiac progenitor cells in single ventricle physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ Res 2017 120 1162 1173. doi: 10.1161/CIRCRESAHA.116.310253.
107. Oh H, Ito H, Sano S, Challenges to success in heart failure: cardiac cell therapies in patients with heart diseases. J Cardiol 2016 68 361 367. doi: 10.1016/j.jjcc.2016.04.010.
108. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, Galang G, Zhang Y, Schoenhoff F, Van Eyk J, Marbán L, Marbán E, Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012 125 100 112. doi: 10.1161/CIRCULATIONAHA.111.042598.
109. Hare JM, Fishman JE, Gerstenblith G, Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012 308 2369 2379. doi: 10.1001/jama.2012.25321.
110. Hong KU, Guo Y, Li QH, Cao P, Al-Maqtari T, Vajravelu BN, Du J, Book MJ, Zhu X, Nong Y, Bhatnagar A, Bolli R, c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One 2014 9 e96725. doi: 10.1371/journal.pone.0096725.
111. Yoon CH, Koyanagi M, Iekushi K, Seeger F, Urbich C, Zeiher AM, Dimmeler S, Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 2010 121 2001 2011. doi: 10.1161/CIRCULATIONAHA.109.909291.
112. van Berlo JH, Molkentin JD, An emerging consensus on cardiac regeneration. Nat Med 2014 20 1386 1393. doi: 10.1038/nm.3764.
113. Malliaras K, Ibrahim A, Tseliou E, Liu W, Sun B, Middleton RC, Seinfeld J, Wang L, Sharifi BG, Marbán E, Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. EMBO Mol Med 2014 6 760 777. doi: 10.1002/emmm.201303626.
114. Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ, Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ Res 2016 118 95 107. doi: 10.1161/CIRCRESAHA.115.305373.
115. Ibrahim AG, Cheng K, Marbán E, Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2014 2 606 619. doi: 10.1016/j.stemcr.2014.04.006.
116. Kishore R, Khan M, More than tiny sacks: stem cell exosomes as cell-free modality for cardiac repair. Circ Res 2016 118 330 343. doi: 10.1161/CIRCRESAHA.115.307654.
117. Agarwal U, George A, Bhutani S, Ghosh-Choudhary S, Maxwell JT, Brown ME, Mehta Y, Platt MO, Liang Y, Sahoo S, Davis ME, Experimental, systems, and computational approaches to understanding the microRNA-mediated reparative potential of cardiac progenitor cell-derived exosomes from pediatric patients. Circ Res 2017 120 701 712. doi: 10.1161/CIRCRESAHA.116.309935.
118. Gallet R, Dawkins J, Valle J, Simsolo E, de Couto G, Middleton R, Tseliou E, Luthringer D, Kreke M, Smith RR, Marban L, Ghaleh B, Marban E, Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J 2017 38 201 211. doi: 10.1093/eurheart/ehw240.
119. Prabhu SD, Frangogiannis NG, The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res 2016 119 91 112. doi: 10.1161/CIRCRESAHA.116.303577.
120. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007 13 952 961. doi: 10.1038/nm1613.
121. Rathod RH, Prakash A, Kim YY, Germanakis IE, Powell AJ, Gauvreau K, Geva T, Cardiac magnetic resonance parameters predict transplantation-free survival in patients with fontan circulation. Circ Cardiovasc Imaging 2014 7 502 509. doi: 10.1161/CIRCIMAGING.113.001473.
122. Latus H, Gummel K, Klingel K, Moysich A, Khalil M, Mazhari N, Bauer J, Kandolf R, Schranz D, Apitz C, Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy. J Cardiovasc Magn Reson 2015 17 34. doi: 10.1186/s12968-015-0142-0.
123. Bayeva M, Sawicki KT, Butler J, Gheorghiade M, Ardehali H, Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail 2014 7 680 691. doi: 10.1161/CIRCHEARTFAILURE.113.000912.
124. Puntmann VO, Peker E, Chandrashekhar Y, Nagel E, T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res 2016 119 277 299. doi: 10.1161/CIRCRESAHA.116.307974.
125. Rutz T, de Marchi SF, Schwerzmann M, Vogel R, Seiler C, Right ventricular absolute myocardial blood flow in complex congenital heart disease. Heart 2010 96 1056 1062. doi: 10.1136/hrt.2009.191718.
126. Luan Y, Zhang ZH, Wei DE, Zhao JJ, Kong F, Cheng GH, Wang YB, Implantation of mesenchymal stem cells improves right ventricular impairments caused by experimental pulmonary hypertension. Am J Med. Sci 2012 343 402 406. doi: 10.1097/MAJ.0b013e31822dc5d3.
127. Liu J, Han Z, Han Z, He Z, Mesenchymal stem cells suppress CaN/NFAT expression in the pulmonary arteries of rats with pulmonary hypertension. Exp Ther Med 2015 10 1657 1664. doi: 10.3892/etm.2015.2722.
128. Liu J, Han Z, Han Z, He Z, Mesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension. Exp Ther Med 2016 11 467 475. doi: 10.3892/etm.2015.2953.
129. Bishop T, Ratcliffe PJ, HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res 2015 117 65 79. doi: 10.1161/CIRCRESAHA.117.305109.
130. Liu H, Fisher SA, Hypoxia-inducible transcription factor-1alpha triggers an autocrine survival pathway during embryonic cardiac outflow tract remodeling. Circ Res 2008 102 1331 1339. doi: 10.1161/CIRCRESAHA.107.167858.
131. Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, Shannon P, Jaeggi E, Tabori U, Keller G, Mital S, Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation. Am J Pathol 2013 183 720 734. doi: 10.1016/j.ajpath.2013.05.022.
132. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA, Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005 46 2116 2124. doi: 10.1016/j.jacc.2005.08.045.
133. Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, Sutcliffe D, Gerard RD, Bruick RK, Shohet RV, Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One 2010 5 e11693. doi: 10.1371/journal.pone.0011693.
134. Cai Z, Luo W, Zhan H, Semenza GL, Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc Natl Acad Sci USA 2013 110 17462 17467. doi: 10.1073/pnas.1317158110.
135. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G, Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009 104 1209 1216. doi: 10.1161/CIRCRESAHA.109.197723.
136. Hwang HJ, Chang W, Song BW, Antiarrhythmic potential of mesenchymal stem cell is modulated by hypoxic environment. J Am Coll Cardiol 2012 60 1698 1706. doi: 10.1016/j.jacc.2012.04.056.
137. Feric NT, Radisic M, Strategies and challenges to myocardial replacement therapy. Stem Cells Transl Med 2016 5 410 416. doi: 10.5966/sctm.2015-0288.
138. van Rooij E, Marshall WS, Olson EN, Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008 103 919 928. doi: 10.1161/CIRCRESAHA.108.183426.
139. van Rooij E, Olson EN, MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012 11 860 872. doi: 10.1038/nrd3864.
140. Uchida S, Dimmeler S, Long noncoding RNAs in cardiovascular diseases. Circ Res 2015 116 737 750. doi: 10.1161/CIRCRESAHA.116.302521.
141. Smith T, Rajakaruna C, Caputo M, Emanueli C, MicroRNAs in congenital heart disease. Ann Transl Med 2015 3 333. doi: 10.3978/j.issn.2305-5839.2015.12.25.
142. Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, Nonogi H, Ma X, Weng H, Hirokawa G, Asada T, Kakinoki S, Yamaoka T, Fukushima Y, Iwai N, MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull 2013 36 48 54
143. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M, Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012 492 376 381. doi: 10.1038/nature11739.
144. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E, Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011 124 1537 1547. doi: 10.1161/CIRCULATIONAHA.111.030932.
145. Adam O, Löhfelm B, Thum T, Gupta SK, Puhl SL, Schäfers HJ, Böhm M, Laufs U, Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012 107 278. doi: 10.1007/s00395-012-0278-0.
146. Creemers EE, van Rooij E, Function and therapeutic potential of noncoding RNAs in cardiac fibrosis. Circ Res 2016 118 108 118. doi: 10.1161/CIRCRESAHA.115.305242.
147. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Ito E, Sougawa N, Kawamura T, Daimon T, Shimizu T, Okano T, Toda K, Sawa Y, Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation 2013 128 S87 S94. doi: 10.1161/CIRCULATIONAHA.112.000366.
148. Shiba Y, Gomibuchi T, Seto T, Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 2016 538 388 391. doi: 10.1038/nature19815.
149. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L, Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011 471 225 229. doi: 10.1038/nature09747.
150. Jung JH, Fu X, Yang PC, Exosomes generated from iPSC-derivatives: new direction for stem cell therapy in human heart diseases. Circ Res 2017 120 407 417. doi: 10.1161/CIRCRESAHA.116.309307.
151. Nam YJ, Song K, Luo X, Daniel E, Lambeth K, West K, Hill JA, DiMaio JM, Baker LA, Bassel-Duby R, Olson EN, Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci USA 2013 110 5588 5593. doi: 10.1073/pnas.1301019110.
152. Wada R, Muraoka N, Inagawa K, Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proc Natl Acad Sci USA 2013 110 12667 12672. doi: 10.1073/pnas.1304053110.
153. Cao N, Huang Y, Zheng J, Spencer CI, Zhang Y, Fu JD, Nie B, Xie M, Zhang M, Wang H, Ma T, Xu T, Shi G, Srivastava D, Ding S, Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science 2016 352 1216 1220. doi: 10.1126/science.aaf1502.
154. Bersell K, Arab S, Haring B, Kühn B, Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009 138 257 270. doi: 10.1016/j.cell.2009.04.060.
155. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, Li T, Liu X, Xu Y, Li X, Zhou M, A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 2010 55 1907 1914. doi: 10.1016/j.jacc.2009.12.044.
156. Zwetsloot PP, Végh AM, Jansen of Lorkeers SJ, van Hout GP, Currie GL, Sena ES, Gremmels H, Buikema JW, Goumans MJ, Macleod MR, Doevendans PA, Chamuleau SA, Sluijter JP, Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical studies. Circ Res 2016 118 1223 1232. doi: 10.1161/CIRCRESAHA.115.307676.
157. Martin-Rendon E, Meta-analyses of human cell-based cardiac regeneration therapies: what can systematic reviews tell us about cell therapies for ischemic heart disease? Circ Res 2016 118 1264 1272. doi: 10.1161/CIRCRESAHA.115.307540.
158. Gyöngyösi M, Wojakowski W, Navarese EP, Moye LÀ ACCRUE Investigators Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res 2016 118 1254 1263. doi: 10.1161/CIRCRESAHA.115.307347.
159. Zwetsloot PP, Gremmels H, Assmus B, Koudstaal S, Sluijter JP, Zeiher AM, Chamuleau SA, Responder definition in clinical stem cell trials in cardiology: will the real responder please stand up? Circ Res 2016 119 514 518. doi: 10.1161/CIRCRESAHA.116.308733.
160. Kobayashi J, Yoshida M, Tarui S, Hirata M, Nagai Y, Kasahara S, Naruse K, Ito H, Sano S, Oh H, Directed differentiation of patient-specific induced pluripotent stem cells identifies the transcriptional repression and epigenetic modification of NKX2-5, HAND1, and NOTCH1 in hypoplastic left heart syndrome. PLoS One 2014 9 e102796. doi: 10.1371/journal.pone.0102796.
161. Suzuki G, Young RF, Leiker MM, Suzuki T, Heart-derived stem cells in miniature swine with coronary microembolization: novel ischemic cardiomyopathy model to assess the efficacy of cell-based therapy. Stem Cells Int 2016 2016 6940195. doi: 10.1155/2016/6940195.
162. Tomita-Mitchell A, Stamm KD, Mahnke DK, Kim MS, Hidestrand PM, Liang HL, Goetsch MA, Hidestrand M, Simpson P, Pelech AN, Tweddell JS, Benson DW, Lough JW, Mitchell ME, Impact of MYH6 variants in hypoplastic left heart syndrome. Physiol Genomics 2016 48 912 921. doi: 10.1152/physiolgenomics.00091.2016.